Disease: Gastric Cancer
Trial Design: Phase 2
We partnered NeuVax with Dr. Reddy’s Laboratories Ltd, an international pharmaceutical company based in India, for the commercialization of NeuVax in that region. Dr. Reddy’s is responsible for conducting a Phase 2 gastric cancer trial, which is expected to initiate in 2016.
Trial Design and Eligibility
This trial will be run in India with our partner, Dr. Reddy’s Laboratories and is expected to initiate in 2016.
About the Disease
According to the National Institute of Health, gastric (stomach) cancer is a disease in which malignant (cancer) cells form in the lining of the stomach. Almost all gastric cancers are adenocarcinomas (cancers that begin in cells that make and release mucus and other fluids). Other types of gastric cancer are gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, and lymphomas. Infection with bacteria called Helicobacter pylori (H. pylori) is a common cause of gastric cancer and age, diet, and stomach disease can affect the risk of developing gastric cancer. Gastric cancer is often diagnosed at an advanced stage because there are no early signs or symptoms.
*NeuVax™ is an investigational product. Efficacy has not been established.